2-氨基烟酸乙酯 | 13362-26-0

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2-氨基烟酸乙酯
• 中文别名: 2-氨基吡啶-3-甲酸乙酯
• 英文名称: 2-aminopyridine-3-carboxylic acid ethyl ester
• 英文别名: ethyl 2-aminonicotinate；ethyl 2-aminopyridine-3-carboxylate
• CAS: 13362-26-0
• 化学式: C₈H₁₀N₂O₂
• mdl: MFCD01569452
• 分子量: 166.18
• InChiKey: KIAGEDYOPMHRRB-UHFFFAOYSA-N

物化性质

• 熔点：
  96-98°C
• 沸点：
  133°C/12mmHg(lit.)
• 密度：
  1.192±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于二甲基亚砜、甲醇

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  65.2
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2933399090
• 危险类别：
  IRRITANT
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  | 冰箱 |

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Ethyl 2-aminonicotinate
Product Name:
Synonyms: Ethyl 2-amino-3-pyridinecarboxylate; Ethyl 2-aminopyridine-3-carboxylate

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
Ethyl 2-aminonicotinate
Ingredient name:
CAS number: 13362-26-0

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C8H10N2O2
Molecular weight: 166.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-氨基烟酸乙酯 在 sodium ethanolate 、 二异丁基氢化铝 、 碳酸氢钠 作用下， 以 乙醇 、 二氯甲烷 、 水 为溶剂， 反应 15.0h， 生成 ethyl α-azido-β-(imidazo[1,2-a]pyridin-8-yl)propenoate
  参考文献：
  名称：

  咪唑的官能化乙烯基衍生物的杂环化。

  摘要：

  咪唑并[1,2-a]吡啶的官能化乙烯基衍生物的杂环化使用半经验AM1和从头算的方法在理论上进行了探索。制备了一系列官能化的乙烯基衍生物（叠氮基，氨基和碳二亚胺基团），用于转化为吡咯并氮杂吲哚19-22，咪唑并[1，x]-，（x = 5、6、7、8），[2,6] -和[2,7]萘啶28-30、35-38通过热反应。在乙烯基位于5位的情况下，还观察到围成环。对实验和理论数据进行了比较和讨论。

  DOI：

  10.1021/jo015582x
• 作为产物：
  描述：

  2-氨基烟酸 在 硫酸 作用下， 以 乙醇 为溶剂， 反应 16.0h， 以95%的产率得到2-氨基烟酸乙酯
  参考文献：
  名称：

  两个6元稠合N杂环的便捷组装：通过Cu介导的反应快速获得新颖的小分子。

  摘要：

  已经开发了一种快速，通用且一锅的Cu介导的多米诺骨牌反应，可轻松组装两个六元稠合N杂环，从而产生新颖的小分子作为PDE4的潜在抑制剂。

  DOI：

  10.1039/c2cc37070k

文献信息

• Synthesis, Crystal Structure, and DFT Study of a New Derivative of Pyrido[2,3-d]pyrimidine
  作者：Liyuan Deng、Hong Sun、Weiyin Hu、Wanpeng Liao、Zhixu Zhou、Hongyan Pan

  DOI：10.1134/s1070363221120197

  日期：2021.12

  N-4-[(6-bromopyrido[2,3-d]pyrimidin-4-yl)oxy]phenyl}morpholine-4-carboxamide has been synthesized as a derivative of pyrido[2,3-d]pyrimidine that demonstrates antitumor, antibacterial, anti-inflammatory, and antimicrobial activities. Synthesis of the target compound based on 2-aminonicotinic acid as the starting material has included its esterification, bromination, cyclization, and substitution reactions

  N-4-[(6-bromopyrido[2,3-d]pyrimidin-4-yl)oxy]phenyl}morpholine-4-carboxamide 已被合成为吡啶并[2,3-d]嘧啶的衍生物，证明了抗肿瘤、抗菌、抗炎和抗菌活性。以2-氨基烟酸为起始原料的目标化合物的合成包括其酯化、溴化、环化和取代反应。产物的结构经 1H 和 13C NMR、FT-IR 和单晶 X 射线衍射 (XRD) 证实。通过DFT计算已经接近了化合物的优化结构、静电势和前沿分子轨道（FMO）。该化合物对 A375 细胞具有抗增殖活性。
• Piperazine derivatives
  申请人：——

  公开号：US20030207888A1

  公开（公告）日：2003-11-06

  The present invention relates to compounds of formula (I) 1 as well as pharmaceutically acceptable salts, solvates and esters thereof. These compounds can be used to prepare pharmaceutical compositions for the treatment or prevention of disorders of the central nervous system, damage to the central nervous system, cardiovascular disorders, gastrointestinal disorders, diabetes, obesity and sleep apnoea.

  本发明涉及式(I)1化合物以及药用可接受的盐、溶剂化物和酯。这些化合物可用于制备用于治疗或预防中枢神经系统疾病、中枢神经系统损伤、心血管疾病、胃肠疾病、糖尿病、肥胖和睡眠呼吸暂停的药物组合物。
• [EN] IMIDAZO [1, 2 -A] PYRIDINES AS JNK MODULATORS<br/>[FR] IMIDAZO[1,2-A]PYRIDINES COMME MODULATEURS DE LA JNK
  申请人：HOFFMANN LA ROCHE

  公开号：WO2010097335A1

  公开（公告）日：2010-09-02

  Compounds of formula (I) modulate JNK wherein X1 and X2 are each simultaneously N or CH; X3 is CH-R2 Or N-SO2R, where R is lower alkyl; R1 is aryl or heteroaryl, substituted with 0-3 lower alkyl radicals; R2 is (II), where R3 is H, lower acyl, or an amino acid, or a pharmaceutically acceptable salt thereof.

  式(I)的化合物调节JNK，其中X1和X2同时为N或CH；X3为CH-R2或N-SO2R，其中R为较低的烷基；R1为芳基或杂环芳基，取代为0-3个较低烷基基团；R2为(II)，其中R3为H，较低酰基，或氨基酸，或其药用可接受盐。
• 一种多取代2-氨基吡啶衍生物的合成方法及用途
  申请人：重庆大学

  公开号：CN111004284B

  公开（公告）日：2022-08-05

  本发明属于有机合成化学领域，涉及一种多取代2‑氨基吡啶衍生物的合成方法即用途，该方法以1,2,3‑三嗪类化合物和氰甲基类化合物为底物，在碱性条件下仅通过一步环加成反应合成得到多取代的2‑氨基吡啶衍生物，反应中不涉及危险及管制试剂和药品的使用，为合成多取代2‑氨基吡啶衍生物提供了一种简单、安全、高效和环保的策略。本发明所得产物经过进一步衍生化，可合成得到含2‑氨基吡啶结构的活性分子或药物分子，如活性分子SC‑53606、药物分子阿帕替尼(Apatinib)和奈伟拉平(Nevirapine)。
• INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF
  申请人：Shire Human Genetic Therapies, Inc.

  公开号：US20190284182A1

  公开（公告）日：2019-09-19

  The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.

  本发明提供了作为血浆激肽酶抑制剂并具有相同理想特性的化合物和组合物。